预约演示

更新于：2025-04-14

Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)

更新于：2025-04-14

概要

概要

基本信息

药物类型

预防性疫苗

别名

Circumsporozoite protein hepatitis-B surface antigen fusion protein- GlaxoSmithKline、CSP-HBsAg - GlaxoSmithKlineCSP-HBsAg - GlaxoSmithKline、CSP-HBsAg/SBAS2-GlaxoSmithKline

+ [27]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

比利时 (2015-01-10),

恶性疟

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 126827

关联

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的临床试验

PACTR202409856142141

/ SuspendedN/AIIT

Evaluating antibody responses longitudinally and correlation to clinical malaria in children who received seasonal vaccination with RTS,S/AS01E with and without seasonal malaria chemoprevention in Mali.

开始日期2024-10-01

申办/合作机构-

NCT06424002

/ Not yet recruiting临床4期IIT

The Impact, Feasibility Acceptability and Cost Effectiveness of the RTS,S/AS01 Malaria Vaccine in School Aged Children

Across sub-Saharan Africa, school-age children bear an under-appreciated burden of malaria. An estimated 200 million school-age children are at risk of malaria and in many areas prevalence of infection exceeds 50%. The high infection rates in this group serves as a source of onward parasite transmission, undermining elimination and control efforts. Furthermore, malaria illness and malaria-induced anemia in this age group lead to school absenteeism, and impaired cognitive function and classroom attention, ultimately resulting in reduced academic achievement. Although universal malaria interventions, such as insecticide treated nets (ITNs) and access to prompt diagnosis and treatment are available to school-age children, this age group is the least likely to benefit from these interventions. Furthermore, efficacy of these approaches may be compromised by increasing anti-malarial drug and insecticide resistance. A malaria vaccine could help to avert the burden of malaria in this age group.
The RTS,S/AS01 malaria vaccine has recently been recommended for vaccination of young children (< 24 months) by the World health organization (WHO) after a Phase 3 trial and an implementation trial showed that the vaccine had moderate but significant efficacy to prevent clinical and severe malaria in young children. Previous randomized trials suggest that the vaccine is safe for older children. However, efficacy of the vaccine has never been assessed in school age children. Kamuzu University of Health Sciences in partnership with the Malawian Ministry of Health seeks to evaluate the efficacy of the newly introduced RTSS/AS01 malaria vaccine in school aged children. The study hypothesizes that vaccination will decrease the morbidity and transmission of malaria, as well as improve school absenteeism and educational outcomes.

开始日期2024-06-01

申办/合作机构

Michigan State University

[+2]

PACTR202307828402450

/ Suspended临床3期

The Impact of a combination of the RTS,S/AS01E Malaria Vaccibe and Perennial Malaria Chemoprevention in Ghanaian Children

开始日期2023-08-14

申办/合作机构

PATH Corp.

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的临床结果

登录后查看更多信息

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的转化医学

登录后查看更多信息

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的专利（医药）

登录后查看更多信息

464

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的文献（医药）

2025-03-01·NATURE REVIEWS MICROBIOLOGY

Towards next-generation treatment options to combat Plasmodium falciparum malaria

Review

作者: Fidock, David A. ; Okombo, John ; Fidock, David A

Malaria, which is caused by infection of red blood cells with Plasmodium parasites, can be fatal in non-immune individuals if left untreated. The recent approval of the pre-erythrocytic vaccines RTS, S/AS01 and R21/Matrix-M has ushered in hope of substantial reductions in mortality rates, especially when combined with other existing interventions. However, the efficacy of these vaccines is partial, and chemotherapy remains central to malaria treatment and control. For many antimalarial drugs, clinical efficacy has been compromised by the emergence of drug-resistant Plasmodium falciparum strains. Therefore, there is an urgent need for new antimalarial medicines to complement the existing first-line artemisinin-based combination therapies. In this Review, we discuss various opportunities to expand the present malaria treatment space, appraise the current antimalarial drug development pipeline and highlight examples of promising targets. We also discuss other approaches to circumvent antimalarial resistance and how potency against drug-resistant parasites could be retained.

2025-03-01·LANCET INFECTIOUS DISEASES

Understanding the immunogenicity of RTS,S in infants

Article

作者: Horii, Toshihiro ; Palacpac, Nirianne Marie Q

2025-03-01·LANCET INFECTIOUS DISEASES

The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial

Article

作者: Kusi, Kwadwo Asamoah ; Moncunill, Gemma ; Macià, Dídac ; Mpina, Maximilian ; Dobaño, Carlota ; Kariuki, Simon ; Sorgho, Hermann ; Campo, Joseph J ; Jairoce, Chenjerai ; Mordmüller, Benjamin ; Molinos-Albert, Luis M ; Dosoo, David ; Daubenberger, Claudia ; Agnandji, Selidji Todagbe

BACKGROUND:

The RTS,S/AS01_E malaria vaccine showed lower antibody response and protective efficacy in infants aged 6-12 weeks compared with children aged 5-17 months (for whom this vaccine is recommended). We aimed to study the effect of previous Plasmodium falciparum exposure on the antibody responses to RTS,S/AS01_E vaccination in infants and children, and the mediating effect of baseline (including maternal) anti-circumsporozoite protein (CSP) antibodies.

METHODS:

In this observational study, we included children and infants from six African countries (Burkina Faso, Gabon, Ghana, Kenya, Mozambique, and Tanzania) enrolled in the MAL067 immunology ancillary study of the RTS,S/AS01_E phase 3 clinical trial from March 27, 2009, to Jan 21, 2011. We used comparator-vaccinated infants and children to identify antibody-based signatures of previous P falciparum exposure, which were later applied to RTS,S/AS01_E-vaccinated infants and children. In these participants, we explored the relationship between vaccine antibody immunoglobulin G (IgG) responses measured by ELISA and pre-vaccination serological markers of malaria exposure by assessing the IgG levels against 1000 P falciparum antigens using partial proteome microarrays.

FINDINGS:

We included 718 comparator-vaccinated infants (348 [48%]) and children (370 [52%]) and 606 RTS,S/AS01_E-vaccinated infants (329 [54%]) and children (277 [46%]). Anti-CSP IgG responses to primary vaccination did not correlate with a baseline signature of previous exposure in children, suggesting that prior P falciparum exposure does not significantly affect antibody immunogenicity in children (Pearson's r=-0·02 [95% CI -0·13 to 0·10]). By contrast, high P falciparum exposure signature levels at the time of vaccination in infants, presumably driven by maternally transferred antibodies and declining within the initial 6-12 months of life, correlated with reduced RTS,S/AS01_E responses (r=-0·17 [-0·27 to -0·06]). This negative correlation was stronger for anti-CSP IgG than for the exposure signature or any other more immunogenic blood stage P falciparum antigens (r=-0·42 [-0·50 to -0·33]), persisted after adjustment by baseline levels of the exposure signature (semi-partial correlation r=-0·44 [-0·55 to -0·33]), and involved antibodies to the central NANP region (r=-0·39 [-0·49 to -0·28]) but not the C-terminal region (r=0·02 [-0·10 to 0·15]) of CSP. The negative effect of maternal anti-CSP IgG in infants did not appear to be confounded by other malaria transmission-dependent variables.

INTERPRETATION:

Interference between passive immunity and vaccine response is clinically significant and might affect the implementation of next-generation CSP-based vaccines for young infants and mothers as well as passive immunisation with human monoclonal antibodies.

FUNDING:

US National Institutes of Health, National Institute of Allergy and Infectious Diseases; PATH-Malaria Vaccine Initiative; Spanish Ministerio de Economía y Competitividad (Instituto de Salud Carlos III), European Regional Development Fund and European Social Fund; Fundación Ramón Areces; Spanish Ministry of Science and Innovation; and Generalitat de Catalunya (CERCA Program).

项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的新闻（医药）

2025-03-18

·GlobeNewswire-Health Care

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair March 17, 2025 -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European biotech-focused investment firm with significant experience investing in vaccine companies such as Vaxcyte and ViceBio. Joining Medicxi is an international group of investment funds including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma. “This Series B round will fund the extension of our successful Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead of the Phase 3 program,” said Curevo’s CEO, George Simeon, MBA/MPH. “Designed based upon feedback from regulators and other stakeholders, this short extension trial will begin mid-2025 and serve to set the company for clinical, strategic, and regulatory success.” Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic, helping deliver vaccines against the SARS-CoV-2 virus. He spent nearly 30 years at GlaxoSmithKline, during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix® (shingles), Cervarix® (HPV-induced cervical cancer), Mosquirix® (malaria), Rotarix® (rotavirus gastroenteritis), and Synflorix® (pneumococcal disease). “I have been collaborating with the Curevo team for several weeks now,” stated Dr. Slaoui. “I’m very excited to work with them to help perfect shingles vaccination, adding good tolerability to the exceptional efficacy achieved by the current vaccine. The data so far show Curevo’s adjuvant technology has the attributes to succeed in this endeavor.” Also joining Curevo’s Board of Directors will be Giovanni Mariggi, PhD, co-founder and Partner at Medicxi, an experienced infectious disease investor and board member. “Patients, doctors, and payors are very clear a new shingles vaccine like amezosvatein would be welcome in the global marketplace. Amezosvatein’s activity and improved tolerability profile could allow it to be a significant product in the shingles vaccines market. We are excited to support Curevo’s plan with a streamlined path to approval,” stated Dr. Mariggi. Tal Zaks, MD/PhD, will be joining Curevo’s Board of Directors on behalf of OrbiMed. Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug development at GSK and Sanofi. “OrbiMed has a long history of investing in biotech companies like Curevo seeking to improve healthcare outcomes while creating long-term shareholder value,” said Dr. Zaks. “The fact amezosvatein contains an optimized version of the TLR4 agonist with a known mechanism of action reduces biological risk while providing the competitive advantage of potentially improved tolerability, which should position it as the first choice for people who want to be protected from shingles.” ‘Amezosvatein’ is the assigned non-proprietary name for CRV-101, a non-mRNA adjuvanted subunit vaccine under investigation by Curevo. Like Shingrix, amezosvatein uses a subunit protein antigen called glycoprotein ‘E’ (gE). Targeting the gE antigen is proven to elicit a long-term, protective immune response to prevent shingles. Amezosvatein’s adjuvant contains an optimized version of the TLR4 agonist proven by Shingrix to be biologically active in shingles vaccination. Amezosvatein was engineered to maintain exceptional efficacy and have a best-in-class tolerability profile. The SLA-SE adjuvant formulation was developed at Seattle-based Access to Advanced Health Institute (AAHI) and amezosvatein was licensed from the Mogam Institute for Biomedical Research, a research institute funded by South Korea’s GC Biopharma. Curevo is a privately held, clinical-stage biotechnology company based near Seattle dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The current $4+ billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to vaccine tolerability. For more information visit https://curevovaccine.com/. Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com. OrbiMed is a leading global healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, via private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com. Switzerland-based HBM Healthcare Investments focuses on the healthcare sector, holding and managing an international portfolio of promising companies in the human medicine, biotechnology, medical technology, diagnostics, and related areas. Many of these companies have their lead products already available on the market or are at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (SIX:HBMN). Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences aligning with Sanofi’s mission to bring life-changing treatments to patients worldwide. For more information, please visit www.sanofiventures.com. Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by its TechAtlas internal research division, and Raven, RA Capital's healthcare incubator, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management. Janus Henderson Investors exists to help clients achieve their long-term financial goals. Its active management offers clients the opportunity to outperform passive portfolios over the course of market cycles. With more than 360 investment professionals, Janus Henderson Investors provides access to some of the industry’s most talented and innovative thinkers, spanning equities, fixed income, multi-asset, and alternatives, globally. Its investment teams blend insight, originality, and precision with rigorous analysis, structured processes, and robust risk management. Janus Henderson Investors builds client partnerships on openness and trust, channeling expertise from across the business and communicating the views of its experts in a timely and relevant way. https://www.janushenderson.com/ Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by prominent healthcare and emerging market investors, Adjuvant draws upon its network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics, and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, with a commitment to make these interventions accessible globally. For more information, visit http://www.adjuvantcapital.com Founding investor GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yongin, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines and expanded its global presence with the successful USA market entry of ALYGLO™ (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platforms to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/ The content above comes from the network. if any infringement, please contact us to modify.

疫苗

2025-02-04

·ir.arcturusrx.com

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

SAN DIEGO --(BUSINESS WIRE)--Feb. 4, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui , Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024 . “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate,” said Joseph Payne , President & Chief Executive Officer of Arcturus. “We look forward to working with him as we enter a transformative year of advancing our pipeline of therapeutics and vaccines.” “Arcturus has deep expertise in mRNA delivery for therapeutics and a validated commercial stage vaccines platform,” said Dr. Moncef Slaoui . “I am excited to work with the company during this potentially transformational time with multiple key data readouts across its pipeline.” About Dr. Moncef Slaoui Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG , and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company. Dr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a redesign of GSK’s R&D structure and culture to improve focus on innovation and productivity. As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease. In 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world. He served on the Advisory Committee to the Director of the NIH from 2011 to 2016 and has advised the U.S. President's Council of Advisors on Science and Technology . Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles , completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine , and was a Professor of Immunology at the University of Mons , Belgium . He received an accelerated Master of Business Administration from IMD, Switzerland in 1998. About Arcturus Founded in 2013 and based in San Diego, California , Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan , ARCALIS , focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S. , Europe , Japan , China , and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20250204663825/en/ Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com Source: Arcturus Therapeutics Holdings Inc.

疫苗高管变更信使RNA

2024-11-21

·vicebio.com

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine…

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former Chair of R&D at GlaxoSmithKline and Khurem Farooq, previously CEO of Aiolos, join Board of Directors London, UK, 21 November 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as the appointment of Moncef Slaoui, PhD, and Khurem Farooq to its Board of Directors. Vicebio is progressing into the second stage of its clinical study of VXB-241 and is now enrolling individuals aged 60 years of age and above to evaluate the candidate vaccine’s safety in this vulnerable population. Early data from the study are expected by mid-2025. Vicebio anticipates these data will represent a significant milestone in the clinical validation of its platform. More information on the P1 study can be found on clinicaltrials.gov (NCT06556147). Moncef Slaoui, PhD, and Khurem Farooq join the Board of Directors, effective immediately. Both bring vast experience in vaccine development and biopharmaceutical leadership. Emmanuel Hanon, Chief Executive Officer of Vicebio, said: “In connection with our significant Series B financing, we are building upon our world-class leadership team with the addition of Moncef and Khurem to the Board. Their expertise not only further supports our innovation but will be essential as we continue to advance the Company’s vision to deliver the next generation of respiratory viral vaccines.” At the heart of Vicebio’s innovation is its proprietary Molecular Clamp technology, designed to stabilise viral antigens and enhance protective immunity across multiple respiratory pathogens. This transformative technology supports the development of multivalent respiratory viral vaccines that are ready-to-use, cost-effective, and capable of addressing critical needs in global respiratory health. Moncef Slaoui, PhD, newly appointed Independent Board Member at Vicebio, commented: “Vicebio’s Molecular Clamp technology marks a transformative advancement in vaccine development. It is fantastic to be joining the Board of a company where the technology and novel approach holds the potential to expedite delivery of highly effective and stable vaccines in ready-to-use prefilled syringes.” Khurem Farooq, newly appointed Independent Board Member at Vicebio, added: “Vicebio is at an exciting phase of growth as it looks to advance its pipeline of multivalent vaccines with the potential to prevent a wide range of diseases in a single vaccine.” Moncef Slaoui, PhD, has extensive experience in drug development and commercialisation. He currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Arcturus Therapeutics, Altesa, and Zephyr AI. Under his leadership as Chief Scientific Advisor to Operation Warp Speed, he played a critical role in the rapid development and deployment of multiple of COVID-19 vaccines in the US. Prior to this Moncef’s career at GlaxoSmithKline (GSK) spanned nearly three decades, where he held several senior leadership roles, including being a member of the Board of Directors. He spearheaded GSK’s Pharmaceutical R&D restructuring to improve focus on innovation and productivity, and was instrumental in the development of 14 new vaccines, including Shingrix, to prevent shingles; Cervarix, to prevent cervical cancer and Mosquirix, to prevent malaria. Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles and completed postdoctoral studies at Harvard Medical School and Tufts University. He also holds an accelerated MBA from IMD in Switzerland. Khurem Farooq is an avid biotech entrepreneur with over 20 years of experience in drug development. Khurem was co-founder and CEO of Aiolos Bio, which was acquired by GSK for $1.4bn in February 2024. Prior to this, Khurem served as CEO of Gyroscope, which was acquired by Novartis in 2021 for up to $1.5bn. Khurem was Senior Vice President of the Immunology and Ophthalmology business unit at Genentech, a member of the Roche Group, where he played a key role in the commercialisation and launch strategies of several medicines and contributed to the development of numerous pipeline products. He holds an MBA and a BSc in Biological Sciences, with honours, from Aston University and University of Wolverhampton, respectively. For further information, please contact: Optimum Strategic Communications Mary Clark, Hana Malik, Vareen Outhonesack Tel: +44 (0) 203 922 0889 Email: vicebio@optimumcomms.com Vicebio is backed by a global syndicate of life science investors including Medicxi, UniQuest, TCGX, Goldman Sachs Alternatives, Avoro Ventures and venBio. For more information, please visit: www.vicebio.com About Vicebio Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp Technology. The company was founded with investment from Medicxi and acquired the rights to the Molecular Clamp technology through a license from UniQuest, the commercialization arm of The University of Queensland, Australia. This proprietary technology was developed by Prof. Paul Young, Prof. Daniel Watterson, and Prof. Keith Chappell at UQ. For more information, please visit: https://www.vicebio.com About Medicxi Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need. For more information, please visit: https://www.medicxi.com About UniQuest UniQuest is the commercialisation company of The University of Queensland (UQ). In partnership with UQ researchers, UniQuest creates impact through the commercialisation of UQ intellectual property. Established in 1984, UniQuest’s commercialisation track record positions UQ as the leader of research commercialisation in Australasia. Notable successes include the blockbuster cervical cancer vaccine Gardasil® and start-up companies Spinifex Pharmaceuticals Inc and Inflazome Ltd, which were acquired in two of the largest university start-ups exits in Australian history. UniQuest has also established the Queensland Emory Drug Discovery Initiative (QEDDI), a world-class small molecule drug discovery and development group, dedicated to translating academic biomedical research into drug candidates for partnering. In 2024, UniQuest launched its AUD$32 million UniQuest Extension Fund, an investment fund dedicated to supporting the start-up eco-system at The University of Queensland. For more information, please visit: https://uniquest.com.au/about/ About TCGX TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in pioneering healthcare companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in San Francisco, Palo Alto, and New York City. For more information, please visit: www.tcgcrossover.com Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $450 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, life sciences, private credit, real estate, infrastructure, hedge funds, and sustainability. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets. The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors, and individuals. Goldman Sachs has over $2.8 trillion in assets under supervision globally as of March 31, 2024. About Avoro Ventures Avoro Ventures is a global life sciences investment firm, and an affiliated company of Avoro Capital Advisors, an SEC-registered investment manager based in New York City, with over $6.5 billion in capital primarily focused on supporting emerging life sciences and biotechnology companies. For more information, please visit: www.avorocapital.com About venBio venBio is a life sciences investment firm that partners with industry leaders to build innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs. For more information, please visit: www.venbio.com

疫苗临床1期并购高管变更

100 项与 Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07X	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶性疟	比利时	GSK Plc	2015-01-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
麻疹	临床3期	加纳	GSK Plc	2017-05-10
风疹	临床3期	加纳	GSK Plc	2017-05-10
黄热病	临床3期	加纳	GSK Plc	2017-05-10
乙型肝炎	临床3期	布基纳法索	GSK Plc	2011-11-17
乙型肝炎	临床3期	加纳	GSK Plc	2011-11-17
HIV感染	临床3期	肯尼亚	GSK Plc	2010-07-30
疟疾	临床3期	布基纳法索	GSK Plc	2009-03-27
疟疾	临床3期	加蓬	GSK Plc	2009-03-27
疟疾	临床3期	加纳	GSK Plc	2009-03-27
疟疾	临床3期	肯尼亚	GSK Plc	2009-03-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04661579 (CTgov)	临床2期	恶性疟	620	Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine+Malaria Vaccine RTS,S/AS01E (Group 1: Positive Parasitemia; Anti-malarial Treatment + RTS,S/AS01E Vaccine)	選遞簾遞淵鬱夢選築簾 = 築衊夢築積淵膚簾鏇觸鏇範鏇糧齋窪淵鏇網鑰 (築簾壓選衊願蓋製簾壓, 繭範築糧選艱願獵襯廠 ~ 鏇簾醖餘觸壓願觸鑰製) 更多	-	2024-07-19
				Dihydroartemisinin-piperaquine (DHA/Pip)+Artemether / Lumefantrine+Primaquine+Abhayrab rabies vaccine (Group 4: Positive Parasitemia; Anti-malarial Treatment + Rabies Vaccine)	選遞簾遞淵鬱夢選築簾 = 獵艱衊壓繭憲顧鹹獵範鏇範鏇糧齋窪淵鏇網鑰 (築簾壓選衊願蓋製簾壓, 衊襯廠膚鬱鬱糧鏇醖壓 ~ 顧鏇襯餘願蓋鏇願網範) 更多
NCT03276962 (CTgov)	临床2期	疟疾	1,500	S+RTS,S/AS01E (Full dose) (Fx012-14-mFxD Group)	壓願鬱鹹憲鏇繭築積壓 = 憲夢顧齋網鏇遞網築膚製夢窪糧鹹鏇鑰選窪淵 (醖齋齋繭齋繭構構選衊, 淵壓艱醖糧築獵壓餘壓 ~ 獵網網蓋廠壓遞獵糧窪) 更多	-	2024-05-21
				RTS,S/AS01E (Full dose) (R012-20 Group)	鬱膚醖鬱鏇鏇齋壓簾鑰 = 齋遞夢淵網衊願鬱網壓膚網構衊繭衊鬱鬱衊顧 (憲繭製遞構鏇願願鑰廠, 遞襯醖簾積網壓淵膚遞 ~ 鹹構鬱鏇鏇構製遞醖積) 更多
NCT02699099 (CTgov)	临床3期	黄热病 \| 疟疾 \| 风疹 ... 更多	699	Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (Coad Group)	顧鹽築糧艱獵齋鏇築壓(製艱糧齋廠襯構觸艱醖) = 繭廠繭繭簾糧夢築蓋窪膚廠構築願繭鏇齋範製 (願遞範鏇蓋積壓糧鬱糧, 積積構淵淵糧醖鏇構顧 ~ 淵觸憲窪願繭鬱鬱鬱網) 更多	-	2019-08-29
				Vitamin A+Stamaril+MR-Vac+Candidate Plasmodium falciparum malaria vaccine (RTS,S Group)	顧鹽築糧艱獵齋鏇築壓(製艱糧齋廠襯構觸艱醖) = 範簾糧襯餘獵艱積窪壓膚廠構築願繭鏇齋範製 (願遞範鏇蓋積壓糧鬱糧, 鬱遞鑰簾餘夢顧襯鏇願 ~ 艱積鹹壓廠製鬱遞鬱遞) 更多
NCT02207816 (CTgov)	临床3期	疟疾	3,084	Blood sampling+Polio Sabin Oral Polio Vaccine+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Group)	構淵衊鹹積繭遞醖醖構(築範壓選鬱獵淵積鹹鏇) = 觸鬱網範鑰網齋夢夢壓鑰齋鏇齋襯築淵衊鏇願 (齋憲顧鹽壓積繭壓鬱齋, 憲遞鹽範願簾製餘積蓋 ~ 築糧齋遞餘鏇餘糧鑰艱) 更多	-	2019-08-15
				Blood sampling+Malaria Vaccine 257049 (MALARIA-055 PRI) (GSK257049 Comparator Group)	構淵衊鹹積繭遞醖醖構(築範壓選鬱獵淵積鹹鏇) = 鏇齋餘鏇蓋範衊簾範選鑰齋鏇齋襯築淵衊鏇願 (齋憲顧鹽壓積繭壓鬱齋, 鏇艱夢蓋鏇膚選襯夢構 ~ 鬱構網壓獵觸蓋鹹廠鬱) 更多
NCT02992119 (RTSS, CTgov)	临床2期	疟疾	193	S+AS01B+RTS (Group 1)	齋醖鹽艱鏇繭鹹襯膚選 = 鹽襯積壓憲鬱遞鹽簾積網鹽顧積願醖憲壓鹽廠 (簾獵蓋鹽製鹹壓鑰鑰艱, 願夢鬱遞糧鏇膚遞襯繭 ~ 艱顧憲鏇鹽積衊願鹽膚) 更多	-	2019-07-29
				Double RTS,S/AS01E Fractional dose (Group 2)	齋醖鹽艱鏇繭鹹襯膚選 = 繭蓋醖夢餘積觸繭憲膚網鹽顧積願醖憲壓鹽廠 (簾獵蓋鹽製鹹壓鑰鑰艱, 廠壓艱觸鹽範鹽觸廠觸 ~ 廠壓鏇鑰鏇襯獵艱餘醖) 更多
NCT03162614 (Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults, CTgov)	临床2期	疟疾	154	Sporozoite-infected mosquitoes challenge.+RTS,S/AS01B (AduFx Group)	遞構繭鏇簾鬱淵鏇鹹範 = 憲窪齋鹽積繭遞餘顧廠構淵襯獵鑰淵壓繭簾廠 (選繭網鏇鏇糧憲蓋選鹹, 製窪廠範醖蓋襯艱製餘 ~ 繭遞壓蓋衊醖襯網窪壓) 更多	-	2019-07-24
				Sporozoite-infected mosquitoes challenge.+RTS,S/AS01E (2PedFx Group)	遞構繭鏇簾鬱淵鏇鹹範 = 觸壓糧簾鬱網觸鬱鬱蓋構淵襯獵鑰淵壓繭簾廠 (選繭網鏇鏇糧憲蓋選鹹, 餘襯繭蓋糧膚蓋製壓鏇 ~ 膚鹽壓顧窪襯鑰蓋夢鬱) 更多
NCT01148459 (CTgov)	临床3期	HIV感染 \| 疟疾	200	GSK257049 vaccine (GSK257049 Group)	願鹽鏇範鑰願膚範繭簾 = 製積繭壓齋夢選襯糧鹽簾積積廠夢襯醖廠構鏇 (製獵鬱願壓繭鹽膚窪積, 範築製醖網願願製襯遞 ~ 齋構糧鹽構顧鑰鹹醖顧) 更多	-	2019-01-16
				Verorab (Verorab Group)	願鹽鏇範鑰願膚範繭簾 = 網觸鹹餘鏇鬱衊膚淵廠簾積積廠夢襯醖廠構鏇 (製獵鬱願壓繭鹽膚窪積, 獵窪糧艱範襯鹽憲積艱 ~ 遞艱鏇憲蓋艱築艱獵膚) 更多
NCT00380393 (RTS,S/AS01E, CTgov)	临床2期	恶性疟	894	GSK malaria vaccine 257049 Vaccine (GSK257049 Group)	鏇鹽鑰網醖選壓簾觸淵 = 糧獵膚艱壓廠遞窪積製蓋蓋範蓋遞夢壓築餘遞 (窪糧獵網簾繭齋艱鹽壓, 製鑰鹽鹹憲淵襯網鹽糧 ~ 繭齋淵蓋積齋築衊憲鹽) 更多	-	2018-07-03
				Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine (Rabipur Group)	鏇鹽鑰網醖選壓簾觸淵 = 遞襯壓積觸淵壓鹹鹹網蓋蓋範蓋遞夢壓築餘遞 (窪糧獵網簾繭齋艱鹽壓, 獵餘衊廠網蓋蓋淵鬱憲 ~ 憲壓製鑰遞鹹鏇衊鬱齋) 更多
NCT00360230 (CTgov)	临床2期	疟疾	540	GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (SB257049 F2 0-1 M Group)	積構觸窪築醖願鑰窪淵 = 製壓糧構網獵獵遞鑰選遞夢鹹積構鏇觸衊憲糧 (憲淵築餘憲淵膚窪製積, 遞鹹壓襯築膚範鑰觸構 ~ 製鏇醖顧艱糧鏇膚夢築) 更多	-	2018-02-19
				GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 (SB257049 F1 0-1 M Group)	積構觸窪築醖願鑰窪淵 = 網積艱窪鏇築鏇艱廠繭遞夢鹹積構鏇觸衊憲糧 (憲淵築餘憲淵膚窪製積, 餘簾壓衊鑰夢窪壓夢蓋 ~ 襯鏇簾膚艱觸餘膚願糧) 更多
NCT01323972 (CTgov)	临床3期	疟疾	327	GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (GSK 257049-Lot 1 Group)	衊淵衊淵蓋衊蓋鑰壓夢(遞窪鏇窪齋餘鏇淵鑰遞) = 糧蓋糧鑰繭醖築積願鬱鑰獵製鑰齋鹹蓋簾糧鏇 (淵獵製窪廠餘鏇顧鏇襯, 壓醖襯願鏇積齋遞築範 ~ 獵糧廠襯網鬱簾鑰顧積) 更多	-	2017-08-07
				GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049) (GSK 257049-Lot 2 Group)	衊淵衊淵蓋衊蓋鑰壓夢(遞窪鏇窪齋餘鏇淵鑰遞) = 鏇遞獵廠鹹選顧齋衊鹽鑰獵製鑰齋鹹蓋簾糧鏇 (淵獵製窪廠餘鏇顧鏇襯, 顧鏇繭夢膚鬱製鏇鑰鬱 ~ 製繭淵餘遞艱獵餘憲遞) 更多